Skip to main content

Elopag 20 mg ( Eltrombopag)

Elopag is a brand name associated with eltrombopag, a prescription medicine used to increase platelet production in certain patients with low platelet counts. It belongs to a class of medicines called thrombopoietin receptor agonists (TPO-RAs).

Platelets are essential blood components that help control bleeding and support normal blood clotting. When platelet levels become too low, patients may experience easy bruising, bleeding gums, nosebleeds and other bleeding complications.

Eltrombopag works by stimulating thrombopoietin receptors in the bone marrow. This encourages the development and maturation of megakaryocytes, which are responsible for producing platelets.

Elopag may be used in specific treatment settings involving immune thrombocytopenia, chronic hepatitis C-associated thrombocytopenia and severe aplastic anaemia, depending on the applicable regulatory approval and prescribing information.

Treatment is individualised according to the underlying condition, platelet count, medical history and response to therapy. Eltrombopag is not suitable for every patient with a low platelet count and should only be used under specialist medical supervision.

1. Elopag for Immune Thrombocytopenia (ITP)

One of the established uses of eltrombopag is the treatment of persistent or chronic immune thrombocytopenia (ITP) in eligible patients.

ITP is an autoimmune disorder in which the immune system mistakenly attacks platelets. This can cause platelet levels to fall below the normal range and increase the risk of bleeding.

Some patients with ITP may experience:

  • Easy bruising.
  • Small red or purple spots on the skin.
  • Nosebleeds.
  • Bleeding gums.
  • Heavy menstrual bleeding.
  • Prolonged bleeding after minor injuries.
  • Blood in the urine or stool.

In eligible patients who have not responded adequately to previous treatments, eltrombopag may help increase platelet production.

How Does Elopag Help in ITP?

Eltrombopag stimulates thrombopoietin receptors in the bone marrow. This encourages megakaryocyte development and increases platelet production.

The treatment aims to achieve a platelet count sufficient to reduce bleeding risk. It does not directly remove the autoimmune cause of ITP.

Who May Receive Eltrombopag for ITP?

Depending on the applicable product label, eltrombopag may be prescribed to adults and children with persistent or chronic ITP who have had an insufficient response to treatments such as:

  • Corticosteroids.
  • Immunoglobulins.
  • Splenectomy.

The medicine is generally considered when the patient’s platelet count and clinical condition indicate an increased risk of bleeding.

Treatment Benefits in ITP

Potential benefits for appropriately selected patients include:

  • Increased platelet production.
  • Improved platelet counts.
  • Reduced bleeding risk.
  • An additional treatment option when previous therapies have not worked adequately.
  • Oral administration rather than direct platelet replacement.

Treatment response varies, and regular platelet-count monitoring is necessary.

2. Elopag for Severe Aplastic Anaemia

Severe aplastic anaemia is a serious bone marrow disorder in which the bone marrow cannot produce sufficient blood cells.

This can affect three important blood-cell types:

  • Red blood cells, which carry oxygen.
  • White blood cells, which help fight infections.
  • Platelets, which help control bleeding.

Patients with severe aplastic anaemia may experience tiredness, weakness, frequent infections, bruising and bleeding.

How Does Eltrombopag Help in Aplastic Anaemia?

Eltrombopag stimulates thrombopoietin receptors and supports blood-cell production in the bone marrow.

In severe aplastic anaemia, it may be used as part of a specialist treatment plan to support haematopoiesis, the process through which the bone marrow produces blood cells.

Eltrombopag in Combination Treatment

Reference-product prescribing information includes eltrombopag in combination with standard immunosuppressive therapy for first-line treatment of eligible patients with severe aplastic anaemia.

It is also indicated in certain patients whose condition has not responded adequately to previous immunosuppressive therapy.

The treatment plan may involve additional medicines and specialist monitoring.

Potential Treatment Benefits

For appropriately selected patients, eltrombopag may:

  • Support bone marrow activity.
  • Improve blood-cell production.
  • Contribute to platelet recovery.
  • Support combination treatment strategies.
  • Provide an additional option for selected patients with inadequate responses to previous treatment.

The response is individual, and treatment decisions should be made by a haematology specialist.

3. Elopag for Chronic Hepatitis C-Associated Thrombocytopenia

Chronic hepatitis C is a viral infection that affects the liver. Some patients with chronic hepatitis C develop thrombocytopenia, meaning their platelet counts become abnormally low.

Low platelet levels may make it difficult to initiate or maintain certain treatments, particularly historical interferon-based antiviral regimens.

In specific reference-product prescribing settings, eltrombopag is indicated for thrombocytopenia in patients with chronic hepatitis C to help allow the initiation and maintenance of interferon-based therapy.

Why Can Hepatitis C Patients Have Low Platelets?

Chronic hepatitis C may affect platelet levels through several mechanisms, including:

  • Liver damage and reduced thrombopoietin production.
  • Enlarged spleen and increased platelet sequestration.
  • Changes in bone marrow activity.
  • Immune-related platelet destruction.

The underlying cause and severity of thrombocytopenia vary between patients.

How Does Elopag Support Treatment?

Eltrombopag stimulates platelet production, potentially helping patients reach the platelet levels needed for specific treatment plans.

However, this use requires particular caution because patients with chronic liver disease may have an increased risk of serious liver complications.

Important treatment distinction: The hepatitis C indication in U.S. reference prescribing information specifically relates to interferon-based therapy. Eltrombopag should not be presented as a general treatment for hepatitis C itself or as an established routine addition to modern interferon-free direct-acting antiviral treatment.

4. How Elopag Supports Platelet Production

The main therapeutic action of eltrombopag is stimulation of the thrombopoietin receptor.

Thrombopoietin is a naturally occurring protein that helps regulate platelet production in the bone marrow.

Eltrombopag activates this receptor through a mechanism that stimulates the development and maturation of platelet-producing cells.

The process can be explained in four stages:

Stage 1: Receptor activation

Eltrombopag interacts with thrombopoietin receptors on bone marrow cells.

Stage 2: Cellular signalling

The interaction activates signalling pathways involved in cell growth and development.

Stage 3: Megakaryocyte maturation

The medicine supports the development and maturation of megakaryocytes.

Stage 4: Platelet release

Mature megakaryocytes release platelets into the bloodstream, potentially increasing the circulating platelet count.

The treatment does not guarantee that platelet counts will reach a particular level. Regular blood tests help the doctor assess the response.

5. Potential Benefits of Elopag Treatment

When prescribed for an approved condition, eltrombopag may provide several potential benefits.

Helps Increase Platelet Counts

Eltrombopag stimulates platelet production in the bone marrow and may help patients with certain forms of thrombocytopenia achieve higher platelet counts.

May Help Reduce Bleeding Risk

In appropriately selected patients, an improved platelet count may reduce the risk of bleeding associated with low platelet levels.

Provides an Oral Treatment Option

Eltrombopag is available in oral formulations, allowing patients to take treatment by mouth.

Supports Selected Bone Marrow Treatment Plans

In severe aplastic anaemia, eltrombopag may be included in treatment plans designed to improve blood-cell production.

Offers an Additional Option for Persistent ITP

For selected patients who have not responded adequately to previous ITP treatments, eltrombopag offers another therapeutic approach.

These potential benefits depend on the patient’s diagnosis, response and overall health. They should not be interpreted as a guarantee of treatment success.

6. How Long Does Elopag Treatment Take to Work?

The time needed for eltrombopag to produce a platelet response varies between patients.

Some patients may show changes in platelet counts within the first few weeks, while others may require a longer period of treatment or may not respond adequately.

The response depends on:

  • The underlying condition.
  • Baseline platelet count.
  • Bone marrow function.
  • Previous treatment history.
  • Prescribed dose.
  • Individual response to the medicine.

Doctors use blood-test results to determine whether treatment is working and whether the prescribed plan needs adjustment.

Patients should not increase the dose or take additional tablets to try to achieve a faster response.

7. Elopag Dosage and Treatment Monitoring

The appropriate eltrombopag dose depends on the condition being treated and the patient’s individual circumstances.

Different treatment indications have different dosing recommendations. A dose used for ITP should not automatically be applied to severe aplastic anaemia or hepatitis C-associated thrombocytopenia.

The treating specialist considers:

  • Age.
  • Diagnosis.
  • Platelet count.
  • Liver function.
  • Previous treatment response.
  • Other medicines.
  • Adverse reactions.

Platelet-Count Monitoring

Regular platelet-count testing is essential during treatment.

It helps the healthcare professional determine whether:

  • The medicine is producing a response.
  • The platelet count is increasing too much.
  • The dose needs adjustment.
  • Treatment should be interrupted or discontinued.

Liver-Function Monitoring

Eltrombopag can cause liver toxicity. Liver-function tests should be performed before and during treatment according to the applicable prescribing instructions.

Patients should report yellowing of the skin or eyes, dark urine, unusual tiredness or upper abdominal discomfort.

8. Conditions for Which Eltrombopag Is Not a General Treatment

Eltrombopag should not be considered a treatment for every disease involving low platelet counts.

In particular:

Myelodysplastic syndromes (MDS): U.S. reference prescribing information states that eltrombopag is not indicated for the treatment of patients with MDS.

General bleeding disorders: Eltrombopag is not a universal medicine for bleeding or clotting problems.

Hepatitis C infection itself: Eltrombopag does not eliminate the hepatitis C virus. Its specific reference indication relates to thrombocytopenia that interferes with interferon-based treatment.

All causes of thrombocytopenia: A low platelet count can result from many conditions, and eltrombopag is appropriate only for selected diagnoses.

A specialist should establish the cause of thrombocytopenia before considering treatment.

9. Important Safety Considerations During Treatment

Although eltrombopag may provide important benefits, it also has significant safety considerations.

Patients should be aware of:

  • Liver toxicity.
  • Increased risk of blood clots.
  • Potential hepatic decompensation in chronic hepatitis C treatment settings.
  • Changes in platelet counts.
  • Cataracts reported during treatment.
  • Food and mineral interactions.

Calcium, iron, magnesium, aluminium, zinc and selenium can interfere with eltrombopag absorption. Follow the product-specific instructions about separating doses from these substances.

Regular medical appointments and laboratory monitoring are essential.

10. Who May Benefit From Elopag?

Eltrombopag may be beneficial for patients who meet the treatment criteria for specific approved conditions.

Potential candidates include:

  • Eligible patients with persistent or chronic immune thrombocytopenia.
  • Selected patients with chronic hepatitis C-associated thrombocytopenia when interferon-based therapy is being used.
  • Eligible patients with severe aplastic anaemia.

The final decision depends on medical assessment, local product approval, treatment history, laboratory results and individual risk factors.

Elopag should only be prescribed by a qualified healthcare professional familiar with the patient’s condition.

Frequently Asked Questions About Elopag Uses & Treatment

1. What is Elopag mainly used for?

Elopag contains eltrombopag, which stimulates platelet production. Depending on the approved product indication, it may be used for persistent or chronic immune thrombocytopenia, certain chronic hepatitis C-associated thrombocytopenia treatment settings and severe aplastic anaemia.

2. Is Elopag used to treat low platelet counts?

Yes. Eltrombopag is prescribed for certain conditions involving low platelet counts. It stimulates the bone marrow to produce additional platelets.

3. Can Elopag treat immune thrombocytopenia?

Yes. Eltrombopag is an established treatment option for eligible patients with persistent or chronic ITP who have had an insufficient response to previous treatments.

4. How does Elopag help patients with ITP?

It activates thrombopoietin receptors in the bone marrow, encouraging megakaryocyte development and increasing platelet production. This may help reduce bleeding risk.

5. Is eltrombopag used for severe aplastic anaemia?

Yes. Reference-product prescribing information includes eltrombopag for severe aplastic anaemia in combination with standard immunosuppressive therapy and for certain patients who have not responded adequately to previous immunosuppressive treatment.

6. Can Elopag be used for hepatitis C patients?

Eltrombopag has a specific reference indication for thrombocytopenia associated with chronic hepatitis C to support the initiation and maintenance of interferon-based therapy. It does not treat the hepatitis C virus itself.

7. Does Elopag increase platelet production naturally?

Eltrombopag stimulates the body’s own platelet-producing cells in the bone marrow. It does not provide platelets directly like a platelet transfusion.

8. How long does eltrombopag take to increase platelet counts?

The response varies. Some patients show platelet-count changes within the first few weeks, while others may respond more slowly or inadequately. Regular blood tests help assess treatment effectiveness.

9. Can Elopag cure immune thrombocytopenia?

Eltrombopag can help control low platelet counts in eligible patients, but it is not considered a universal cure for ITP. The duration of treatment and long-term response vary.

10. Is Elopag suitable for everyone with thrombocytopenia?

No. It is intended for specific medical conditions and should only be used after the cause of low platelet counts has been assessed by a healthcare professional.

Medical Disclaimer

This page provides general educational information about the uses and treatment applications of eltrombopag. It is not a substitute for professional medical advice, diagnosis or treatment. Elopag should only be used under the supervision of a qualified healthcare professional. The appropriate treatment, dosage and monitoring plan depend on the patient’s diagnosis and the locally approved product information.

Product verification notice: Everest Pharmaceuticals’ official catalogue lists Elopag 25 mg and Elopag 50 mg. It lists AVAPAG 20 mg separately as avatrombopag, which is a different active ingredient. The specific Elopag 20 mg product strength therefore requires verification before publication. Do not treat avatrombopag and eltrombopag as interchangeable medicines.